Israel Active

Israel’s Restart (see previously) has shifted its focus from rehabilitating IDF veterans, to supporting soldiers wounded in the current war. Its scanners and 3D printers at hospitals instantly make devices to help restore mobility. Restart’s volunteers are mostly wounded veterans themselves.

A CBS program that publicized the life-changing impact of the exoskeleton from Israel’s ReWalk (see previously) that enables wheelchair-bound US veterans to walk. CBS didn’t mention that the product was Israeli or even its name.

Israel’s Theranica (see previously) has reported successful long-term use of its Nerivio Remote Electrical Neuromodulation (REN) device for 409 migraine sufferers in the US. It consistently gave pain relief, functional disability relief and freedom.

Israel’s Magenta Medical (see previously) reported positive results in a 15-patient trial of its Elevate System. The percutaneous Left Ventricular Assist Device (pLVAD) supports circulation in high-risk percutaneous coronary interventions (HR-PCI).

Israel’s Can-Fite (see previously) is developing small molecule medicines that address oncology and inflammatory diseases. It has partnered with Collaborations Pharma to use AI and Machine Learning techniques that significantly reduce development time and costs.

Israeli startups XRHealth (see previously) and CalmiGo (see previously) are donating their anxiety-relieving devices to hospitals, nursing homes, assisted living facilities and mental health centers throughout Israel. XRHealth’s headsets and CalmiGo’s inhalers help relax worried citizens.

Stanford Medicine performed the first spine surgery using the augmented reality technology from Israel’s Surgical Theater (see previously). The successful tumor resection operation employed Surgical Theater’s SyncAR Spine platform.

Israel’s MeMed (see previously) has been awarded nearly $727,800 from the US Biomedical Advanced Research and Development Authority (BARDA) to support a trial of its 15-minute MeMed BV test that distinguishes between bacterial and viral infections.

The US FDA has approved the VasQ External Vascular Support from Israel’s Laminate Medical Technologies (see previously). It follows a US 144-patients study. VasQ safely connects a patient’s arteries and veins to dialysis machines, by creating arteriovenous fistulas or AVFs.

The SmartHeart monitoring system from Israel’s SHL Telemedicine (see previously) is undergoing trials at Imperial College London. It has reduced ER visits by 27.5% and hospital readmission rates by 55%, surpassing expectations.